Creative Diagnostics, a reagent supplier focused on biologics quality control, has expanded its comprehensive range of Products for Hepatic Metabolism. This new line of liver-specific fractions, including Liver Cytosol, Liver Microsomes, and Liver S9 Fractions, comes from various species and can support pharmaceutical researchers and toxicologists in conducting critical in vitro metabolism studies.
The liver plays a central role in human metabolism, processing both beneficial and harmful substances through carbohydrate metabolism, lipid and fatty acid metabolism, protein and amino acid metabolism, and drug metabolism. Most liver diseases result in varying degrees of hepatocyte damage and functional impairment, thereby profoundly affecting metabolic processes. As the primary organ for drug metabolism and the main site of drug-induced toxicity, the liver accounts for over 50% of acute liver failure cases, which leads to the withdrawal or restricted use of approved medications.
Beyond hepatotoxicity, metabolites generated in the liver circulate systemically to other tissues and organs, including the kidneys, heart, brain, intestines, and lungs, as well as tumors. Harnessing drug-metabolite interactions between the liver and other organs can achieve desired therapeutic effects, but such interactions may also lead to unintended toxic side effects. For example, the pre-chemotherapy drug ifosfamide induces nephrotoxicity by producing both the intended antitumor metabolite, 4-hydroxy-IFO, and the nephrotoxic metabolite, chloroacetaldehyde. Therefore, interactions between the liver and other organs must be carefully considered and evaluated in drug metabolism and toxicity studies.
Creative Diagnostics now offers an extensive range of hepatic metabolism related products that enable researchers to study hepatic metabolic processes with high precision and reproducibility. This new product line includes liver products from various species, such as humans, non-human primates, dogs, rats, rabbits, and minipigs. Core products include Liver Cytosol, Liver Microsomes, and Liver S9 Fractions. The company provides comprehensive metabolic research solutions to address challenges encountered during drug development.
"Precise metabolomic analysis is the cornerstone of successful drug development," said the Creative Diagnostics project manager. "By offering a liver metabolism testing product line spanning multiple species, we help our clients in the pharmaceutical industry bridge the gap between in vitro testing and in vivo outcomes, ultimately reducing the risk of clinical failure."
Drug metabolism studies are essential during the evaluation of drugs, and this expanded product portfolio represents a significant advancement for pharmaceutical safety testing. Researchers can access the full catalog of Products for Hepatic Metabolism through the Creative Diagnostics website at https://qbd.creative-diagnostics.com/products-for-hepatic-metabolism.html. The availability of species-specific liver fractions allows for more accurate prediction of human metabolic pathways and potential toxicities before clinical trials, potentially reducing drug development costs and improving patient safety outcomes across the pharmaceutical industry.
